Drug Trial Radar · NCT06452498
Preeclampsia Intervention Netherlands
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Sep 19, 2025
Primary completion
Mar 19, 2029
Study completion Jun 19, 2029
Sponsor
- Lead sponsor
- Amsterdam UMCAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- ZonMw: The Netherlands Organisation for Health Research and Development
- First posted
- Jun 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to find out if pregnant individuals with preterm preeclampsia (PE) who are treated with metformin can stay pregnant for longer, and if this is safe(r) for the mother and child. Preterm PE affects about 1 in 100 pregnant individuals in the Netherlands. Signs of preterm PE can be high blood pressure and protein in the urine in the second half of pregnancy (but before 32-34 weeks of pregnancy). Other symptoms can develop, such as problems with blood clotting and how well the blood cells, liver, lungs, and brain work. The disease can lead to serious complications for both the mother and child. The only way to cure preterm PE is to make sure the child is born, and many times, children have to be delivered (very) early (before 37 weeks). Children born (very) early can suffer from infections, breathing difficulties, and problems in their development. Metformin is a medicine used to treat high blood sugar during and outside of pregnancy. In a previous study in South Africa, women with preterm PE that used metformin were able to safely remain pregnant for an extra week. Similarly, the main goal of the Preeclampsia Intervention NetherLands (PI-NL) study is to see if patients with preterm PE in the Netherlands that use metformin can remain pregnant for a longer time than patients taking a placebo. A placebo is a look-a-like capsule that contains no active ingredients. Researchers, the treating medical team, and participants will not know which participant gets which treatment. In addition, all participants will receive the standard care that all preterm PE patients get.
Conditions
- Pre-Eclampsia Onset Less Than 37 Weeks
- Pre-Eclampsia
- Pre-Eclampsia; Complicating Pregnancy
- Pre-Eclampsia as Antepartum Condition
- Pre-eclampsia or Eclampsia With Pre-existing Hypertension
- Pre-Eclampsia; Affecting Fetus
- HELLP Syndrome Complicating Pregnancy
- HELLP Syndrome
- HELLP
Interventions
Metformin HydrochlorideDrug
Metformin Hydrochloride encapsulated immediate-release tablet of 500 mg, backfilled with cellulose.
PlaceboDrug
Capsule filled with cellulose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of days between randomization and deliveryTime frame: Time between randomization and delivery (up to 37 weeks of gestation)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Amsterdam UMC
Amsterdam, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.